Are you or someone you know struggling with moderate-to-severe atopic dermatitis? If so, you're likely aware of the constant discomfort and impact on quality of life. But there's good news: a recent study offers valuable insights into effective treatments. Researchers at Xiangya Hospital, Central South University, in China, have published a study in Frontiers of Medicine exploring the real-world effectiveness and safety of Janus kinase 1 (JAK1) inhibitors for treating this condition.
Why is this study important? While clinical trials have shown promising results for JAK1 inhibitors like upadacitinib and abrocitinib in treating moderate-to-severe atopic dermatitis (AD), especially in China, real-world data, particularly in Asian populations, has been limited. This study aimed to fill that gap. The researchers recruited 90 patients with moderate-to-severe AD (as defined by an IGA score of 3-4) between June 2022 and June 2023. Of these, 51 received oral abrocitinib (100 mg once daily), and 39 received oral upadacitinib (15mg once daily).
The study meticulously tracked various factors. They assessed patient demographics and clinical characteristics at the start, along with disease severity and quality of life using scores like EASI, IGA, and SCORAD. They also monitored laboratory indicators such as total serum IgE and TEC, both at the beginning and at 2, 4, 16, and 24 weeks after starting treatment.
So, what did they find? The results were encouraging. Both drugs significantly reduced disease severity and improved the quality of life, with noticeable effects as early as Week 2. These improvements were sustained for the entire 24-week study period. By Week 4, patients in both groups showed rapid responses, including achieving EASI-75, EASI-90, IGA 0/1, and PP-NRS4 scores. Serum IgE levels decreased significantly in the abrocitinib group, while TEC levels decreased in both groups. Importantly, there was no statistically significant difference in efficacy between the two drugs after adjusting for other influencing factors.
But here's where it gets interesting... Regarding safety, 27.45% of patients taking abrocitinib and 30.77% of those on upadacitinib reported adverse events (AEs). The most common side effect was acne, but all AEs were mild and resolved with symptomatic treatment. There were no serious AEs, no treatment discontinuations due to AEs, and no deaths related to AEs. This suggests a favorable safety profile for both medications in this patient population.
And this is the part most people miss... The study provides valuable real-world evidence supporting the use of JAK1 inhibitors in Chinese patients with moderate-to-severe AD. However, the researchers also acknowledged some limitations, such as the single-center design, the relatively small sample size, and the 24-week follow-up period. This means the findings may not be generalizable to all populations, and longer-term studies are needed.
What do you think? Do these findings change your perspective on JAK1 inhibitors? Are you surprised by the safety profile? Share your thoughts in the comments below!
